In his weekly clinical update, Dr. Griffin deep dives into infections of dairy cattle with high pathogenic influenza H5N1, how long virus has been circulating and if known anti-influenza antivirals can reduce secondary attack rates, before reviewing the recent statistics on SARS-CoV-2 infection, the guidelines for spring administration of COVID vaccines boosters, whether COVID booster takes associates with long COVID prevalence, discusses the emergency use application of a pre-exposure prophylactic, if administration of oral antiviral therapies can prevent the onset of post-acute sequelae following SARS-CoV-2 infection, continues to dispel the myth of viral rebound, when to use steroids and the benefits of convalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, compares and contrasts the cognitive profile in multiple sclerosis and post-COVID, exercise intolerance following SARS-CoV-2 infection and the epidemiology of the pandemic in a Kenyan refugee camp. For more information about this body of work, listen to TWiV 1088.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode - Technical reports on high path avian influenza (CDC)
- High path cow influenza H5N1 clade 2.3.4.4b (Emerging Infectious Diseases)
- Cow flu flying around for 4 months (CNN)
- Interstate commerce: high path avian influenza in dairy cattle (bioRxiv)
- Oseltamivir and baloxavir marboxil treatment for influenza in household index cases (Influenza and other respiratory viruses)
- COVID-19 national trend (CDC)
- COVID-19 deaths (CDC)
- Spring vaccine advice (CIDRAP)
- Older adult spring booster available (CDC)
- Advisory committee for immunization practices slides (CDC)
- Advisory committee for immunization practices spring 2024 COVID-19 boosters (CDC)
- EUA for pemgarda (FDA)
- CDC Quarantine guidelines (CDC)
- NIH COVID-19 treatment guidelines (NIH)
- Infectious Disease Society guidelines for treatment and management (IDSociety)
- Overuse ofantibiotics for COVID-19: a viral disease (European Soc Clin Micro Inf Dis)
- Molnupiravir safety and efficacy (JMV)
- Convalescent plasma recommendation for immunocompromised (IDSociety)
- Outpatient treatment with concomitant vaccine-boosted convalescent plasma (mBio)
- Updated respiratory virus guidances (CDC)
- What do when your heathcare provider is infected with SARS-CoV-2 (CDC)
- Managing healthcare staffing shortages (CDC)
- Antiviral effect of metformin on SARS-CoV-2 viral load (CID)
- Nirmatrelvir-ritonavir to prevent post-acute sequelae and mortality in SARS-CoV-2 hospitalized patients (Lancet Infectious Diseases)
- Oral antivirals for acute and post-acute sequelae from SARS-CoV-2 infection (Lancet Infectious Diseases)
- Nirmatrelvir-ritonavir for prevention of COVID-19 related hospitalization (American Journal of Therapeutics)
- Nirmatrelvir-ritonavir effectiveness (American Therapeutics)
- Steroids,dexamethasone at the right time (OFID)
- Anticoagulation guidelines (hematology.org)
- Long COVID evidence based review TWiV shout out (TWiV 1088)
- Cognitive profile in multiple sclerosis and post-COVID (Scientific reports)
- Exercise intolerance in long COVID (American Journal of Medicine)
- Epidemiology of SARS-CoV-2 in the Kakuma refugee camp, Kenya (Emergining Infectious Diseases)
- Rohingya refugees (USA for UNHCR)
- Contribute to our Floating Doctors fundraiser
- Letters read on TWiV 1112
- Dr. Griffin’s COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv